Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/bjh.17866 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-term survival of a kidney transplant patient with advanced renal cancer after combination therapy: a case report and literature review.
J Int Med Res
December 2024
Department of Urology, Shaoxing People's Hospital, Shaoxing, Zhejiang, China.
renal transplant carcinoma, especially in the context of bilateral renal carcinoma, is rare and often presents as small, low-grade papillary renal cell carcinoma (RCC). There is currently no consensus or effective treatment for advanced metastatic RCC after kidney transplantation. A 40-year-old man developed renal transplant carcinoma with venous thrombus and lung metastases 13 years after transplantation.
View Article and Find Full Text PDFNovel strategy for comprehensive therapy with sustainably complete response in a patient with limited-stage small cell lung cancer: a case report.
J Int Med Res
December 2024
Department of Oncology Medicine, Affiliated Zhongshan Hospital of Dalian University, Dalian, China.
Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with the poorest prognosis among all types of lung cancer. Developing an effective comprehensive strategy remains a key focus. We herein present the first documented case of a 68-year-old man with limited-stage SCLC who has maintained a complete response (CR) for over 30 months to date.
View Article and Find Full Text PDFVisible-Light-Absorbing Photosensitizer Nanostructures for Treatment of Pathogenic Bacteria and Induction of Systemic Acquired Resistance.
ACS Nano
December 2024
School of Chemistry, Chemical Engineering and Biotechnology, Nanyang Technological University, 21 Nanyang Link, Singapore 637371, Singapore.
Induction of systemic acquired resistance (SAR) in plants to control bacterial diseases has become an effective solution to the problems of agrochemical resistance and ecological environment damage caused by long-term and large-scale use of traditional bactericides. However, current SAR-inducing compounds are often unable to rapidly eliminate pathogenic bacteria in infected plant tissues to prevent further spread of the disease, severely restraining the potential for extensive application in agriculture. Herein, we address the limitations by developing a series of visible-light-absorbing aggregation-induced emission photosensitizers suitable for agricultural use.
View Article and Find Full Text PDFHow I Treat AML relapse after allogeneic HCT.
Blood
December 2024
Dana-Farber Cancer Institute, BOSTON, Massachusetts, United States.
Allogeneic hematopoietic stem-cell transplantation (HCT) is one of the principal curative approaches in the treatment of acute myeloid leukemia (AML); however, relapse post-transplantation remains a catastrophic event with poor prognosis. The incidence of relapse has remained unchanged over the last three decades despite an evolving understanding of the immunobiology of the graft-versus leukemia effect and the immune escape mechanisms that lead to post-HCT relapse. The approach to post-transplant relapse is highly individualized and is dictated both by disease biology and genomics as well as the patient's clinical status at the time of relapse and the interval between relapse and transplantation.
View Article and Find Full Text PDFMenin inhibitors in the treatment of acute myeloid leukemia.
Blood
December 2024
University Medical Center Groningen, Groningen, Netherlands.
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the (oligo)clonal expansion of myeloid progenitor cells. Despite advances in treatment, AML remains challenging to cure, particularly in patients with specific genetic abnormalities. Menin inhibitors have emerged as a promising therapeutic approach, targeting key genetic drivers of AML such as KMT2A rearrangements and NPM1 mutations.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!